- Home
- MGNX vs FORA Comparison
MGNX vs FORA Comparison
Compare MGNX & FORA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MGNX
- FORA
- Stock Information
- Founded
- MGNX 2000
- FORA 2014
- Country
- MGNX United States
- FORA United States
- Employees
- MGNX N/A
- FORA N/A
- Industry
- MGNX Biotechnology: Pharmaceutical Preparations
- FORA Computer Software: Prepackaged Software
- Sector
- MGNX Health Care
- FORA Technology
- Exchange
- MGNX Nasdaq
- FORA Nasdaq
- Market Cap
- MGNX 97.2M
- FORA 62.7M
- IPO Year
- MGNX 2013
- FORA N/A
- Fundamental
- Price
- MGNX $1.36
- FORA $2.06
- Analyst Decision
- MGNX Hold
- FORA Strong Buy
- Analyst Count
- MGNX 9
- FORA 1
- Target Price
- MGNX $5.33
- FORA $5.00
- AVG Volume (30 Days)
- MGNX 378.7K
- FORA 6.9K
- Earning Date
- MGNX 05-13-2025
- FORA 06-06-2025
- Dividend Yield
- MGNX N/A
- FORA N/A
- EPS Growth
- MGNX N/A
- FORA N/A
- EPS
- MGNX N/A
- FORA N/A
- Revenue
- MGNX $154,050,000.00
- FORA $22,332,001.00
- Revenue This Year
- MGNX N/A
- FORA $13.31
- Revenue Next Year
- MGNX $45.52
- FORA N/A
- P/E Ratio
- MGNX N/A
- FORA N/A
- Revenue Growth
- MGNX 255.31
- FORA 9.00
- 52 Week Low
- MGNX $0.99
- FORA $1.85
- 52 Week High
- MGNX $5.77
- FORA $4.03
- Technical
- Relative Strength Index (RSI)
- MGNX 39.88
- FORA 50.21
- Support Level
- MGNX $1.44
- FORA $1.92
- Resistance Level
- MGNX $1.58
- FORA $2.16
- Average True Range (ATR)
- MGNX 0.11
- FORA 0.12
- MACD
- MGNX -0.02
- FORA 0.00
- Stochastic Oscillator
- MGNX 17.65
- FORA 51.28
About MGNX MacroGenics Inc.
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.
About FORA Forian Inc.
Forian Inc provides a suite of Software, data management capabilities, and proprietary data and analytics to optimize and measure operational, clinical, and financial performance for customers within the traditional and emerging life sciences, healthcare payer, and provider segments, as well as cannabis dispensaries, manufacturers, and cultivators.